Oversea Chinese Banking CORP Ltd purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,651 shares of the company’s stock, valued at approximately $97,000.
Several other institutional investors and hedge funds also recently bought and sold shares of TEVA. Bank of New York Mellon Corp boosted its holdings in Teva Pharmaceutical Industries by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company’s stock valued at $17,609,000 after purchasing an additional 28,920 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 12.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company’s stock worth $1,118,000 after acquiring an additional 13,069 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 4.7% in the 1st quarter. MetLife Investment Management LLC now owns 95,953 shares of the company’s stock worth $901,000 after acquiring an additional 4,300 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 3.7% in the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock worth $391,081,000 after acquiring an additional 1,494,814 shares during the last quarter. Finally, Great West Life Assurance Co. Can lifted its holdings in shares of Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company’s stock worth $4,137,000 after acquiring an additional 16,134 shares during the last quarter. 50.39% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Stock Down 0.8 %
Shares of NYSE TEVA opened at $7.33 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $6.78 and a 12 month high of $11.44. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 2.28. The company has a 50-day simple moving average of $8.28 and a 200-day simple moving average of $9.13.
Wall Street Analysts Forecast Growth
TEVA has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, May 25th. They issued an “equal weight” rating and a $10.00 price objective on the stock. Evercore ISI upgraded shares of Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a report on Thursday, May 18th. Finally, StockNews.com began coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, May 18th. They set a “buy” rating on the stock. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average price target of $10.67.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Featured Articles
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- FuelCell Is Back To Realistic Valuation
- MarketBeat Week in Review – 6/4 – 6/9
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
- What is a Mutual Fund? How Does it Work?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
